Acrigen Biosciences
Berkeley
About Acrigen Biosciences
Acrigen Biosciences is dedicated to making gene editing safe. It develops technologies to improve efficiency and enhance the safety of CRISPR-Cas based gene editing. CRISPR-Cas system which enables the precise enzymatic editing of genes is one of the most exciting and promising techniques to be developed in the last few years with the capability to prevent or cure many devastating diseases. It was founded in 2019 and is headquartered in Berkeley, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.2M
- Funding stage: Seed
- Last round: Grant (Feb 2022)
- Website: acrigen.com
Industries & Categories
Biotechnology, Genetics, Life Science
Social Profiles
Canonical: https://fsome.com/organization/acrigen-biosciences-146359 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.